Ma Tao, Hao Xiao-Meng, Chen Hong-Dan, Zheng Min-Hui, Chen Xiao-Geng, Cai Shuang-Long, Zhang Jin
The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Sci Rep. 2025 Jan 2;15(1):386. doi: 10.1038/s41598-024-84785-3.
Triple-negative breast cancer (TNBC) is a diverse category with a subset that displays particularly aggressive characteristics, referred to in this study as "rapid relapse" TNBC (rrTNBC). This term is defined as the occurrence of distant metastasis or death within 24 months post-diagnosis. The paper mainly studies the clinicopathologic traits of TNBC patients experiencing rapid disease progression and chemotherapy resistance and identify predictive markers for this outcome. A retrospective evaluation was conducted on 2294 TNBC patients who underwent surgery at Tianjin Medical University Cancer Hospital. Of these, 369 were categorized as experiencing rapid relapse, while 1925 did not relapse rapidly. Logistic regression analysis was applied to determine potential markers predictive of rapid relapse post-chemotherapy. Both univariate and multivariate logistic regression analyses pinpointed several predictors of rapid relapse in TNBC patients post-chemotherapy. These include age at diagnosis (≥ 50 years, OR = 0.413, 95% CI: 0.289-0.590), postoperative pathological T staging (T2, OR = 2.557, 95% CI: 1.766-3.703; T3 + T4, OR = 3.725, 95% CI: 1.355-10.454), and N staging (N1, OR = 3.056, 95% CI: 2.021-4.619; N2, OR = 6.917, 95% CI: 3.920-12.206; N3, OR = 24.597, 95% CI: 11.875-50.948). Additionally, sTIL expression (intermediate, OR = 0.204, 95% CI: 0.139-0.300; high, OR = 0.020, 95% CI: 0.011-0.035) and Her2 expression (Her2 1+, OR = 0.470, 95% CI: 0.321-0.688) were identified as protective indicators against rapid relapse. A predictive model incorporating these predictors yielded a C-index of 0.898 in the training set and 0.938 in the validation set, with respective Brier scores of 0.079 and 0.073. The study successfully established and validated a predictive model for rapid disease progression and chemotherapy resistance in TNBC patients post-chemotherapy, demonstrating robust discrimination and accuracy.
三阴性乳腺癌(TNBC)是一个多样化的类别,其中一部分具有特别侵袭性的特征,在本研究中称为“快速复发”TNBC(rrTNBC)。该术语定义为诊断后24个月内发生远处转移或死亡。本文主要研究疾病进展迅速且对化疗耐药的TNBC患者的临床病理特征,并确定这一结果的预测标志物。对在天津医科大学肿瘤医院接受手术的2294例TNBC患者进行了回顾性评估。其中,369例被归类为快速复发,而1925例未快速复发。应用逻辑回归分析来确定化疗后快速复发的潜在预测标志物。单因素和多因素逻辑回归分析均确定了TNBC患者化疗后快速复发的几个预测因素。这些因素包括诊断时的年龄(≥50岁,OR = 0.413,95%CI:0.289 - 0.590)、术后病理T分期(T2,OR = 2.557,95%CI:1.766 - 3.703;T3 + T4,OR = 3.725,95%CI:1.355 - 10.454)和N分期(N1,OR = 3.056,95%CI:2.021 - 4.619;N2,OR = 6.917,95%CI:3.920 - 12.206;N3,OR = 24.597,95%CI:11.875 - 50.948)。此外,sTIL表达(中等,OR = 0.204,95%CI:0.139 - 0.300;高,OR = 0.020,95%CI:0.011 - 0.035)和Her2表达(Her2 1+,OR = 0.470,95%CI:0.321 - 0.688)被确定为预防快速复发的保护指标。纳入这些预测因素的预测模型在训练集中的C指数为0.898,在验证集中为0.938,相应的Brier评分为0.079和0.073。该研究成功建立并验证了TNBC患者化疗后疾病进展迅速和化疗耐药的预测模型,显示出强大的区分能力和准确性。